Short Interest in Veru Inc. (NASDAQ:VERU) Rises By 14.3%

Veru Inc. (NASDAQ:VERU - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 14,620,000 shares, a growth of 14.3% from the January 15th total of 12,790,000 shares. Based on an average trading volume of 2,950,000 shares, the short-interest ratio is currently 5.0 days.

Hedge Funds Weigh In On Veru

Institutional investors and hedge funds have recently made changes to their positions in the stock. MPM Bioimpact LLC acquired a new position in Veru during the 4th quarter worth approximately $2,788,000. Oppenheimer & Co. Inc. increased its holdings in shares of Veru by 181.6% during the fourth quarter. Oppenheimer & Co. Inc. now owns 1,120,586 shares of the company's stock valued at $729,000 after acquiring an additional 722,644 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Veru by 337.4% during the fourth quarter. JPMorgan Chase & Co. now owns 255,782 shares of the company's stock worth $166,000 after purchasing an additional 197,307 shares during the period. Barclays PLC lifted its holdings in shares of Veru by 309.2% in the 3rd quarter. Barclays PLC now owns 184,777 shares of the company's stock worth $142,000 after purchasing an additional 139,617 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Veru by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company's stock valued at $2,261,000 after purchasing an additional 131,720 shares during the period. Institutional investors own 47.16% of the company's stock.

Veru Stock Up 8.0 %

VERU traded up $0.04 during trading on Wednesday, hitting $0.60. The company's stock had a trading volume of 2,072,324 shares, compared to its average volume of 5,060,276. The firm has a market capitalization of $87.10 million, a P/E ratio of -2.28 and a beta of -0.54. Veru has a twelve month low of $0.47 and a twelve month high of $1.92. The stock's fifty day moving average price is $0.71 and its 200-day moving average price is $0.76.

Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%. Equities research analysts expect that Veru will post -0.26 EPS for the current fiscal year.

Analyst Ratings Changes

VERU has been the topic of a number of recent analyst reports. Oppenheimer restated an "outperform" rating and issued a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of Veru in a research note on Thursday, January 2nd.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.